TARDBP and proteostasis deficiencies: Furthermore, the fact that geneticmodifiers uncovered in screens for TDP-43 and FUS proteotoxicty are surprisinglydistinct argues further that there are likely different underlying pathogenicmechanisms for FUS and TDP-43 proteinopathies.